Our Portfolio

portfolioAvexegen Therapeutics

Avexegen Therapeutics

Therapies for Gastrointestinal Diseases

Avexegen Therapeutics is an early stage development company working on novel and revolutionary therapies for the $10 Billion GI Market. Our lead drug candidate, Neuregulin-4 (NRG-4), offers a completely new approach to directly heal damaged and inflamed gut tissue in patients with Crohn’s Disease and ulcerative colitis, as well as in premature infants with necrotizing enterocolitis (NEC).

Visit Avexegen Therapeutics's website.